---
title: "Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic impact on families"
description: "Formulary evidence on Darovasertib (IDE196, LXS196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic impact on families. Topics: Practical and financial support from family members; Travel and accommodation costs of treatment at specialist centers; Concern about the financial burden of self-funded treatment on the family; Dependence on a spouse, partner, child, or caregiver. 4 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description/economic-impact-on-families"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic impact on families

<a id="heading-2.2.1.8.3"></a>

## 2.2.1.8.3 Economic Impact of Metastatic uveal melanoma on Families

<a id="topic-2.2.1.8.3-1"></a>

### Practical and financial support from family members

> “About half of the patients described the support received from close family or friends as being important for emotional support, assisting in decision-making or practical support such as transport, finances, understanding of medical information, and support with activities of daily living when they were unwell. Of these patients, most specified their partner as their main source of support.”
> “However, some of them expressed regret for the emotional and practical burden their disease and treatment conferred to their family”

Source: [Ng et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11045555/)

<a id="topic-2.2.1.8.3-2"></a>

### Travel and accommodation costs of treatment at specialist centers

> “Some treatments required patients to travel interstate or even overseas to access them, in two cases separating women from their family for long periods. In these instances, financial burden from travel and accommodation became a significant issue.”

Source: [Ng et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11045555/)

> “The survey was conducted on the SurveyMonkey platform, consisted of 22 questions, and was available in English from April 17th-May 17th, 2021.”
> “50% of participants similarly indicated that they require some level of assistance with travel costs.”
> “Therefore, while patients are willing to travel, it poses a significant financial hardship that is not always mitigated by provincial health insurance.”

Source: [Ocumel Canada survey report, the ocular melanoma landscape in Canada (2021)](https://saveyourskin.ca/_files/ugd/e08cdc_41dfa819c12143e2a766b820f9cdeeab.pdf)

<a id="topic-2.2.1.8.3-3"></a>

### Concern about the financial burden of self-funded treatment on the family

> “Aside from uncertainty, participant concerns focused largely on time, travel and financial burdens from new generation treatments, which were available only at specialist cancer centres and rarely subsidised by government schemes.”
> “Participants expressed worry about their ability to self-fund treatment and the potential they might have to decide whether to pursue expensive new treatments if their current one failed, especially the financial burden this might place on their family for increasingly uncertain gains with each new line of therapy”

Source: [Luckett et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12105258/)

<a id="topic-2.2.1.8.3-4"></a>

### Dependence on a spouse, partner, child, or caregiver

> “The majority of respondents at various risk for metastatic disease, and especially those with metastatic disease, also reported occasional dependence on a spouse, partner, child and/or caregiver.”

Source: [Haystack Project press release, uveal melanoma Patient Oriented Value report (2022)](https://haystackproject.org/s/Press-Release-UV-POV-vf.pdf)

## Related pages
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Terms and abbreviations](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations.md)
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product information and disease description](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical evidence](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic information and modeling report](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: References](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references.md)
